Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Veeva Systems (VEEV) has drawn fresh attention after ...
Veeva Systems (VEEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Veeva Systems shares were 7% higher, at $235.89, after the company said its board of directors approved a share-repurchase program with authorization to buy up to $2 billion of its shares. Under the ...
The latest announcement is out from Veeva Systems ( (VEEV)). On January 5, 2026, Veeva Systems announced that its board had authorized the company’s first-ever share repurchase program, allowing the ...
Our CRM business is healthy, and it is an important part of Veeva, but it's not the major -- it's not the largest part of Veeva anymore, that’s for sure. A significant statement from Peter Gassner, ...
The Details: Veeva reported quarterly earnings of $2.04 per share, which beat the analyst estimate of $1.95. Quarterly revenue of $811.2 million beat the Street estimate of $792.82 million.
The latest announcement is out from Veeva Systems ( (VEEV)). On November 17, 2025, Veeva Systems Inc. announced that Kristine Diamond, the Chief Accounting Officer, will resign from her position ...
PLEASANTON, Calif. and MIAMI, Oct. 16, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) and OpenEvidence today announced the formation of a long-term partnership to jointly create and market Open Vista ...
Join us for an exclusive webinar where we unveil our new Python API designed to streamline trading as a price taker in FX Options. Whether you are a seasoned quant or trader looking to incorporate ...
The Investment Committee give you their top stocks to watch for the second half. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your ...
Veeva Systems delivered strong Q2 results, with robust revenue growth and a fortress-like balance sheet, reinforcing its leadership in the biopharma sector. The company resolved its legal dispute with ...